{
    "Trade/Device Name(s)": [
        "BD Phoenix\u2122M Automated Microbiology System Moxifloxacin (0.0625-8 \u00b5g/mL)",
        "BD Phoenix\u2122M Automated Microbiology System for use with the antimicrobial agent moxifloxacin (0.0625-8 \u00b5g/mL) - Streptococcus ID/AST or AST only Phoenix Panels"
    ],
    "Submitter Information": "Becton, Dickinson and Company",
    "510(k) Number": "K062206",
    "Predicate Device Reference 510(k) Number(s)": [
        "K020321",
        "K020323",
        "K020322"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON"
    ],
    "Summary Letter Date": "September 8, 2006",
    "Summary Letter Received Date": "August 1, 2006",
    "Submission Date": "July 31, 2006",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility Devices"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Moxifloxacin"
    ],
    "Specimen Type(s)": [
        "Pure culture isolates of aerobic and facultative anaerobic Gram-negative and Gram-positive bacteria"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BD Phoenix\u2122M Automated Microbiology System"
    ],
    "Method(s)/Technology(ies)": [
        "Broth-based microdilution",
        "Redox indicator growth detection",
        "Automated susceptibility testing",
        "Automated identification"
    ],
    "Methodologies": [
        "Antimicrobial susceptibility testing (AST)",
        "Organism identification (ID)",
        "MIC determination"
    ],
    "Submission Type(s)": [
        "Instrument",
        "Panel",
        "Reagent",
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for BD Phoenix\u2122M Automated Microbiology System with moxifloxacin for quantitative antimicrobial susceptibility testing of Streptococcus isolates",
    "Indications for Use Summary": "Intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most Gram-negative aerobic and facultative anaerobic bacteria and Gram-positive bacteria (Staphylococcus, Enterococcus, Streptococcus) isolates from pure culture using moxifloxacin on Streptococcus ID/AST or AST only Phoenix panels",
    "fda_folder": "Microbiology"
}